宇瞳光學(300790.SZ):2021年度擬向銀行等金融機構申請不超12億元授信額度
格隆匯3月24日丨宇瞳光學(300790.SZ)公佈,公司於2021年3月24日召開第二屆董事會第十二次會議審議通過《關於公司2021年度向銀行等金融機構申請授信額度的議案》,具體內容如下:
為滿足公司生產經營和發展的需要,提高資金營運能力,公司及全資子公司上饒市宇瞳光學有限公司預計2021年度擬向銀行等金融機構申請總額度不超過人民幣12億元的綜合授信,在此額度內由公司根據實際資金需求進行銀行借貸。
為便於公司2021年度向銀行申請授信額度工作順利進行,公司董事會擬授權董事長張品光全權處理公司向銀行等金融機構申請授信額度相關的一切事務,由此產生的法律、經濟責任全部由公司承擔,授權期限自2020年度股東大會審議通過之日起至2021年度股東大會召開之日止。授信起始時間及額度最終以銀行等金融機構實際審批為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.